Daily Endocrinology Research Analysis
Analyzed 48 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology papers stand out today: a multicenter RCT shows once-weekly lonapegsomatropin improves body composition in adults with GH deficiency; a human genetics-mechanistic study links MEI4 loss-of-function to premature ovarian insufficiency via defective meiotic DSB formation; and a randomized crossover trial demonstrates that daytime natural light exposure improves glycemic control and shifts substrate metabolism toward fat oxidation in type 2 diabetes.
Research Themes
- Long-acting growth hormone therapy in adult GHD
- Genetic mechanisms of female reproductive endocrinology
- Chronobiology and metabolic control in type 2 diabetes
Selected Articles
1. Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.
In a 38-week, multicenter randomized trial of 259 adults with GHD, once-weekly lonapegsomatropin significantly reduced trunk percent fat and trunk fat mass and increased total lean mass versus placebo, with safety comparable to daily somatropin. These data support lonapegsomatropin as a lower-burden weekly alternative for adult GHD.
Impact: This high-quality RCT demonstrates clinically meaningful body composition improvements with a once-weekly GH prodrug, addressing adherence and treatment burden in adult GHD.
Clinical Implications: Lonapegsomatropin can be considered as a once-weekly alternative to daily somatropin in adult GHD, with expected reductions in trunk fat and gains in lean mass and a familiar safety profile.
Key Findings
- Primary endpoint met: trunk percent fat decreased vs placebo (LS mean difference −2.04%, P<.001).
- Total body lean mass increased vs placebo (LS mean difference +1.70 kg, P<.0001).
- Trunk fat mass decreased vs placebo (LS mean difference −0.70 kg, P=.0053).
- Safety and tolerability comparable to daily somatropin.
Methodological Strengths
- Multicenter, randomized, placebo-controlled design with active comparator.
- Prespecified primary endpoint and adequate sample size across 116 centers.
Limitations
- Duration limited to 38 weeks; long-term outcomes (CV events, fractures) not assessed.
- Active comparator arm was open-label, which may introduce performance bias.
- Body composition surrogates rather than hard clinical outcomes.
Future Directions: Evaluate long-term clinical outcomes, patient-reported outcomes, adherence, and cost-effectiveness of once-weekly GH vs daily therapy; assess subgroups and real-world effectiveness.
CONTEXT: Adult growth hormone (GH) deficiency (GHD) is characterized by metabolic abnormalities caused by insufficient GH production. Lonapegsomatropin, a prodrug administered once weekly, was designed to provide sustained release of unmodified somatropin to reduce the burden of daily somatropin injections. OBJECTIVE: To evaluate the efficacy and safety of lonapegsomatropin vs placebo as treatment for adults with GHD. DESIGN: The foresiGHt trial was a multicenter, randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial (NCT04615273). SETTING: This trial was conducted at 116 centers in North America, Europe, and Asia-Pacific. PARTICIPANTS: This trial randomized and dosed 259 adults with GHD. INTERVENTIONS: Participants were randomized 1:1:1 to receive once-weekly lonapegsomatropin, once-weekly placebo, or daily somatropin for 38 weeks. MAIN OUTCOME MEASURE: The primary efficacy endpoint was change from baseline in trunk percent fat at week 38. Secondary efficacy endpoints included change from baseline in trunk fat mass and total body lean mass. RESULTS: At week 38, lonapegsomatropin significantly reduced trunk percent fat (-1.68% vs +0.37%; LS mean difference -2.04%, P<.001), increased total body lean mass (+1.60 kg vs -0.11 kg; LS mean difference 1.70 kg, P<.0001), and reduced trunk fat mass (-0.48 kg vs +0.22 kg; LS mean difference -0.70 kg, P=.0053) vs placebo. The safety and tolerability profile of lonapegsomatropin was comparable to somatropin. CONCLUSIONS: The foresiGHt trial met its primary efficacy endpoint by demonstrating superiority of lonapegsomatropin vs placebo with similar safety and tolerability, supporting its potential as a once-weekly treatment option for adults with GHD.
2. MEI4 variations drive female reproductive disorders via impaired oocyte abundance and developmental potential.
WES of 1,530 women with POI identified an enrichment of MEI4 loss-of-function variants. Functional assays show these variants impair meiotic DSB formation and uncover a role for the MEI4 C-terminus in stabilizing the MEI4–REC114 subcomplex, providing mechanistic insight into diminished ovarian reserve and oocyte competence.
Impact: This study elucidates a causal genetic mechanism for POI by linking MEI4 loss-of-function to defective meiotic DSB formation and complex stabilization, advancing diagnostic targets in reproductive endocrinology.
Clinical Implications: MEI4 should be considered in genetic testing panels for POI; mechanistic insights may inform counseling on prognosis and fertility preservation strategies.
Key Findings
- WES of 1,530 POI patients across two cohorts identified enrichment of MEI4 loss-of-function variants.
- MEI4 variants impair meiotic DSB formation in vitro.
- The MEI4 C-terminus stabilizes the MEI4–REC114 subcomplex on chromosome axes, a previously unrecognized function.
Methodological Strengths
- Large human genetic cohort with focused WES analysis.
- Mechanistic validation via in vitro functional assays revealing protein complex stabilization role.
Limitations
- Abstract does not detail control cohorts or effect sizes; external replication not specified.
- Translational studies to clinical phenotypes and in vivo validation are needed.
Future Directions: Replicate MEI4 findings in diverse populations, quantify penetrance/expressivity, and develop clinical-grade assays; explore therapeutic modulation of DSB pathway components.
Meiotic DNA double-strand break (DSB) formation is pivotal for oocyte development, regulating both ovarian reserve and oocyte developmental potential. Mutations in DSB formation genes have been associated with premature ovarian insufficiency (POI) and adverse pregnancy outcomes in women. Whole exome sequencing in 1530 POI patients across two Chinese cohorts identifies loss-of-function variants in the DSB formation gene, MEI4, enriched in POI. These MEI4 variants impair DSB formation in vitro and reveal a previously unrecognized function of the MEI4 C-terminus in stabilizing the MEI4-REC114 subcomplex on the chromosome axes. Additionally, Mei4
3. Natural daylight during office hours improves glucose control and whole-body substrate metabolism.
In a randomized crossover study (n=13), natural daylight during office hours increased CGM time-in-range and shifted substrate metabolism toward fat oxidation, with circadian phase advance in primary myotubes and multi-omic changes. Results suggest daylight as a low-cost environmental intervention to support glucose control in T2D.
Impact: This trial integrates chronobiology with metabolism, demonstrating that real-world light exposure can acutely improve glycemic metrics and substrate use, with mechanistic readouts across tissues.
Clinical Implications: Optimizing daylight exposure in workplaces and daily routines may complement medical therapy in T2D; architectural and occupational policies could be leveraged to enhance metabolic health.
Key Findings
- Randomized crossover exposure to daylight vs constant artificial light increased CGM time-in-range in T2D.
- Whole-body substrate metabolism shifted toward greater fat oxidation during daylight exposure.
- Primary human myotubes showed a circadian phase advance; serum metabolome, lipidome, and monocyte transcriptome changed with daylight.
Methodological Strengths
- Randomized crossover design with within-subject control.
- Multi-omic profiling coupled with CGM and ex vivo circadian assays.
Limitations
- Small sample size (n=13) and short intervention periods (4.5 days).
- Generalizability may be limited; long-term clinical outcomes not assessed.
- Blinding to light condition is not feasible, potential expectancy effects.
Future Directions: Scale to larger, diverse cohorts with longer follow-up, test timing/duration dose-response, and integrate workplace daylight interventions with clinical endpoints.
Because 80%-90% of our time is spent indoors and daylight is the main synchronizer of the central biological clock, the chronic lack of daylight is increasingly considered as a risk factor for metabolic diseases, such as type 2 diabetes. In a randomized crossover design (NCT05263232), 13 individuals with type 2 diabetes were exposed to natural daylight facilitated through windows vs. constant artificial lighting during office hours for 4.5 consecutive days. Continuous glucose monitoring revealed that participants spent more time in the normal glucose range, and whole-body substrate metabolism shifted toward a greater reliance on fat oxidation during daylight. Primary myotubes cultured from skeletal muscle biopsies displayed a phase advance after daylight exposure. Multi-omic analyses revealed daylight-induced differences in serum metabolites, lipids, and monocyte transcripts. Our findings suggest that natural daylight exposure has a positive metabolic impact on individuals with type 2 diabetes and could support the treatment of metabolic diseases.